Clofibride

Clofibride
Clinical data
ATC code	C10AB10 (WHO) ;
Pharmacokinetic data
Metabolism	Hydrolyzed to clofibric acid; hepatic glucuronidation
Elimination half-life	12 hours (clofibric acid)
Excretion	Renal (mostly) and fecal
Identifiers
	IUPAC name 3-(dimethylcarbamoyl)propyl 2-(4-chlorophenoxy)-2-methylpropanoate;
CAS Number	26717-47-5;
PubChem CID	160134;
ChemSpider	140758 ;
UNII	0S9SLS3L93;
KEGG	D07188 ;
ChEMBL	ChEMBL1697831;
CompTox Dashboard (EPA)	DTXSID1022841 ;
ECHA InfoCard	100.043.542
Chemical and physical data
Formula	C16H22ClNO4
Molar mass	327.81 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(OC(C(=O)OCCCC(=O)N(C)C)(C)C)cc1;
	InChI InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3 ; Key:CXQGFLBVUNUQIA-UHFFFAOYSA-N ;
	(verify)

Clofibride is a fibrate. Clofibride is a derivative of clofibrate. In the body it is converted into 4-chlorophenoxyisobutyric acid (clofibric acid),^[1] which is the true hypolipidemic agent.^[2]^[3] So clofibride, just like clofibrate is a prodrug of clofibric acid.

References

↑ "Clofibride".
↑ Entry on Clofibrat. at: Römpp Online. Georg Thieme Verlag, retrieved 06. Mai 2020.
↑ Romics L (November 1988). "[Basic principles of drug therapy of hyperlipoproteinemia]". Orvosi Hetilap (in Hungarian). 129 (45): 2391–2399. PMID 3054710.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by adding missing information.

[1] "Clofibride".

[römpp-2] Entry on Clofibrat. at: Römpp Online. Georg Thieme Verlag, retrieved 06. Mai 2020.

[Romics_1988-3] Romics L (November 1988). "[Basic principles of drug therapy of hyperlipoproteinemia]". Orvosi Hetilap (in Hungarian). 129 (45): 2391–2399. PMID 3054710.

[1]

[2]

[3]

v t e PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Bocidelpar Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists: FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone EHP-102 (VCE-003.2) Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMsTooltip Selective PPARγ modulator: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

This page was redesigned at the edge.

References